Kenneth Galbraith

Biotech VC and Leader.Ocean Conservationist. Fit'ba Fanatic. Bruins fan to the core🏒

[Zymeworks Inc. @ZymeworksInc]

At the annual ESMO Gynaecological Cancers Conference this week, we will present an efficacy analysis of our folate receptor alpha (FRα) -targeting antibody-drug conjugate by (FRα) expression level.

“We are highly encouraged by these data, which continue to demonstrate the differentiated profile of ZW191 and its potential to deliver meaningful clinical benefit across a broad population of patients with ovarian and endometrial cancers,” said Sabeen Mekan, M.D., Senior Vice President and Chief Medical Officer of Zymeworks. “The response rate observed in FRα-positive ovarian cancer patients compares favorably with currently available therapies, while maintaining meaningful activity in patients with lower levels of FRα expression. Together these encouraging data on durability, progression-free survival, and manageable safety profile further strengthen our confidence in the program and reinforce the ability of our ADC platform to generate differentiated therapeutics.”

View the poster: https://t.co/EVxoczeIID

Read our press release: https://t.co/9cYDoFzj2L

#ADC #ESMOGYNE #ovariancancer #endometrialcancer

[Zymeworks Inc. @ZymeworksInc]

Congratulations to the team at @BeOneMedicines on this important milestone! The FDA’s Priority Review highlights the potential of this combination approach in the first-line treatment of HER2-positive gastroesophageal adenocarcinoma—an area with significant unmet need for patients.

#GEA #oncology

[Zymeworks Inc. @ZymeworksInc]

We’re pleased @GovCanHealth has approved our HER2-targeted therapy for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer. This milestone reflects years of dedication from our teams and partners—and reinforces our commitment to developing therapies for patients with high unmet medical need.

We’re grateful to the patients, investigators, and teams who made this possible and remain focused on delivering meaningful impact where it’s needed most.

[Sam Fazeli @SamFazeli8]

A timely conversation with Ken Galbraith of $ZYME https://t.co/c41HOeFHkf

[Zymeworks Inc. @ZymeworksInc]

Zymeworks Chair & CEO Kenneth Galbraith on Bloomberg Intelligence (@BBGIntelligence) with @SamFazeli8 to talk about the company's new strategic initiatives. https://t.co/Mne7c40kNO

Galbraith explains how Zymeworks shifted from a platform-heavy biotech to a partnership-driven model that balances scientific innovation with capital discipline. The conversation covers Zymeworks' path to market, lessons from partnering with @JazzPharma and @BeOneMedicines, the value of Azymetric antibody design, and why retaining upside through milestones and royalties could reshape long-term value creation.

[Zymeworks Inc. @ZymeworksInc]

Wishing everyone a wonderful new year!

[Zymeworks Inc. @ZymeworksInc]

Zymeworks CEO Kenneth Galbraith joined the host of the BioSpace Denatured podcast Jennifer Smith-Parker and Josh Smiley, CEO of Zai Lab. The three discussed key themes leading up to #JPM2026. Tune in here: https://t.co/6lOifhlwl2

[Zymeworks Inc. @ZymeworksInc]

Zymeworks is thrilled to share our continued progress at upcoming conferences in January.

Read the full press release: https://t.co/zVM7Gy3Ccp

[Zymeworks Inc. @ZymeworksInc]

We’re proud to celebrate Dr. Raffaele Colombo, recipient of the 2024 George R. Pettit Individual Input to the Field Award at this year’s @World_ADC Conference in San Diego.

This award recognizes the individual who made the most significant contribution to the #ADC field over the past year — and we’re thrilled to see Raffaele’s leadership, innovation, and dedication to advancing ADC science recognized at this level.

Congratulations, Raffaele, and thank you for your impact on the field and on our team!

@raffcolo

[Zymeworks Inc. @ZymeworksInc]

Today we're excited to announce a significant evolution in our long-term strategy, one that positions Zymeworks for a more durable, predictable, and value-generating future. Building on the positive Phase 3 data for Ziihera® and the continued advancement of pasritamig, we are transitioning from a biotech model to a royalty-driven organization supported by a productive internal R&D engine.

This approach allows us to optimize the value of our licensed products, expand a diversified portfolio of revenue-generating healthcare assets, and reinvest in differentiated innovation where we can make the greatest impact for patients.

This is an important moment for Zymeworks as we align our business to pursue sustainable growth, capital efficiency, and long-term shareholder value while delivering meaningful advances through our scientific platforms.

Read the full announcement here https://t.co/ZUdAIBZh0w and join our conference call today at 8:30 am ET to learn more https://t.co/3jUGVe3gvv

[Zymeworks Inc. @ZymeworksInc]

We're excited to announce positive results from the HERIZON-GEA-01 Phase 3 trial, in collaboration with @JazzPharma and @BeOneMedicines. This pivotal study investigated our HER2-targeted bispecific antibody in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.

Read the press release: https://t.co/oVKfYZYGBh

[Zymeworks Inc. @ZymeworksInc]

We are excited to announce three poster presentations at the @sitcancer 40th Annual Meeting, taking place this week in National Harbor, MD.

Title: Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity
Abstract Number: 853

Title: TriTCE Co-stim: A differentiated T cell engager platform with conditional cis CD28 co-stimulation is transferable to diverse targeting strategies
Abstract Number: 1196

Title: High-throughput quantitative characterization of cytotoxic antibody-drug conjugates using spheroid models reveals important considerations in potential molecular mechanisms of ADC resistance
Abstract Number: 57

Learn more: https://t.co/jSMNVbkQsj

#immunotherapy #immunooncology #cancer #SITC25

[Zymeworks Inc. @ZymeworksInc]

We’re excited to be at World ADC San Diego this week, sharing our learnings and innovations in ADC development!

Tuesday, November 4 at 11:00 am
Geoff Winters, Director & Functional Lead, ADC Process Development presents "Lessons learned from discovery and CMC development"

Wednesday, November 5 at 3:00 pm
Stuart Barnscher, Senior Director, Preclinical Programs, ADC Therapeutic Development presents "Development and therapeutic potential of a novel Zymeworks Ly6E-targeting ADC against solid tumors"

If you’ll be at #WorldADC, we’d love to connect!

[Zymeworks Inc. @ZymeworksInc]

Zymeworks presents preliminary Phase 1 clinical data for our antibody-drug conjugate (ADC) targeting folate receptor-⍺ at the AACR-NCI-EORTC International Conference today in Boston. The data provides insights into the potential of the ADC in patients with advanced solid tumors, including #ovariancancer, #endometrialcancer, and non-small cell lung cancer.

Join our Investor & Analyst webcast today at 3:30 pm ET with lead author Patricia LoRusso, DO, PhD (hc), FAACR and Zymeworks senior management to discuss the data presented - register here: https://t.co/s8eOBxeYWS

Read key data highlights from the presentation here: https://t.co/2E6vOnYwLv

[Zymeworks Inc. @ZymeworksInc]

We're excited to be part of @lifesciences_bc's upcoming Invest in BC event taking place October 28-29 in Vancouver! Stuart Barnscher, Senior Director, ADC Therapeutic Development will present on behalf of Zymeworks and participate in a panel session. Learn more: https://t.co/eguSq8nJMi

[Zymeworks Inc. @ZymeworksInc]

Zymeworks management team will report third quarter 2025 financial results on November 6. Following the announcement, the team will host a conference call at 4:30 pm ET to discuss financial results and provide a corporate update.

Read the press release: https://t.co/aOILtvTl0k

[Zymeworks Inc. @ZymeworksInc]

We’re excited to join the global oncology community at #ESMO25 as it celebrates 50 years of innovation in cancer research. If you’re attending, we’d love to connect and discuss how together we can shape the future of oncology.

#cancerresearch

[Zymeworks Inc. @ZymeworksInc]

Zymeworks will present preliminary Phase 1 clinical data for our antibody-drug conjugate (ADC) targeting folate receptor-⍺ at the AACR-NCI-EORTC International Conference on October 23. The data will provide insights into the potential of the ADC in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung cancer.

Title: Preliminary results from a phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α-targeting antibody-drug conjugate, in patients with advanced solid tumors
Date/Time: Thursday, October 23, 2025 at 12:30-4:00 pm Eastern Time (ET)

In addition, a live webcast will be held with lead author Patricia LoRusso, DO, PhD (hc), FAACR and Zymeworks senior management on October 23, 2025 at 3:30 pm ET to discuss the data presented.

Read the press release: https://t.co/yLRYj6HVu0

#antibodydrugconjugate #targets25 #ovariancancer #nsclc #endometrialcancer

[Zymeworks Inc. @ZymeworksInc]

At Zymeworks, we’re thankful for so much — our dedicated team and their families, our partners, and everybody on the front lines of cancer research and care. Wishing you all a happy and peaceful Thanksgiving.

[Zymeworks Inc. @ZymeworksInc]

Zymeworks is proud to announce the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer. Dr. Schayowitz brings nearly 20 years of experience in oncology drug development to Zymeworks, having led dozens of global development programs from initiation through approval and commercialization.

“Adam joins Zymeworks at a pivotal moment, as we continue to advance a range of therapeutic candidates in areas of high unmet need, and prepare additional candidates for the clinic,” said Kenneth Galbraith. “With recent milestones including the investigational new drug clearance for ZW251 and expanded global approvals of zanidatamab, we are focused on execution across our development pipeline and expanding our strategic partnerships. Adam’s deep expertise in oncology, R&D, and strategic business development make him uniquely suited to help accelerate these efforts and unlock additional value from our R&D portfolio.”

Read the press release: https://t.co/J5A7rELMBx